Incidence and impact of resistance against approved antiretroviral drugs

Deenan Pillay*, Stephen Taylor, Douglas D. Richman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

106 Citations (Scopus)

Abstract

More than 15 antiretroviral drugs are now available for clinical use, and have led to significant reductions in morbidity and mortality for HIV infected individuals. Nevertheless, antiviral drug resistance emerges to all these drugs, which limits their benefit. This review addresses the biological basis of antiretroviral drug resistance, and the prevalence of specific drug resistance associated mutations in patients treated with the three currently available classes of agents, namely nucleoside analogue reverse transcriptase inhibitors, non nucleoside reverse transcriptase inhibitors and protease inhibitors. In addition, data on prevalence of HIV drug resistance in untreated individuals published to date are summarised, and the implications of potential transmission of drug resistant HIV is discussed. Copyright (C) 2000 John Wiley and Sons, Ltd.

Original languageEnglish
Pages (from-to)231-253
Number of pages23
JournalReviews in Medical Virology
Volume10
Issue number4
DOIs
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Dive into the research topics of 'Incidence and impact of resistance against approved antiretroviral drugs'. Together they form a unique fingerprint.

Cite this